Moreover, it is interesting to note that in endometrial cancer, a malignancy largely driven by estrogen signaling (as is luminal BC), estrogen decreases APC/CFZR1 levels, causing a subsequent increase in SKP2-mediated p27 degradation; and SKP2 knockdown or inhibition prevents estrogen-driven p27 degradation and cell growth45,57. Here, SKP2 is linked to endometrial cancer.